Guidelines for the administration of aminosalicylatesin patients with inflammatory bowel diseases


Authors: L. Prokopová 1;  D. Ďuricová 2,3;  M. Bortlík 2,5;  V. Zbořil 1;  M. Lukáš 2,4;  Pracovní Skupina Pro Idiopatické Střevní Záněty Čgs Čls Jep
Authors‘ workplace: Interní-gastroenterologická klinika LF MU a FN Brno 1;  Klinické a výzkumné centrum pro střevní záněty, ISCARE Lighthouse a 1. LF UK v Praze 2;  Farmakologický ústav 1. LF UK v Praze 3;  Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK v Praze 4;  Interní klinika 1. LF UK a ÚVN v Praze 5
Published in: Gastroent Hepatol 2012; 66(5): 391-400
Category: IBD: Guidelines

Konsenzus Pracovní skupiny pro idiopatické střevní záněty ČGS ČLS JEP

Overview

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
8. 8. 2012

Accepted:
15. 10. 2012


Sources

1. Caprilli R, Cesarini M, Angelucci E et al. The long journey of salicylates in ulcerative colitis: The past and the future. J ­Crohns Colitis 2009; 3(3): 149–156.

2. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active thera­peutic moiety of sulphasalazine. Lancet 1977; 2(8044): 892–895.

3. Klotz U, Maier K, Fischer C et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303(26): 1499–1502.

4. Schroder H, Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 1972; 13(4): 278–284.

5. Travis SPL, Stange EF, Lemann M et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2(1): 24–62.

6. Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-amino­salicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2011; 33(9): 996–1009.

7. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther 2008; 28(6): 663–673.

8. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006; 24 (Suppl 1): 2–9.

9. Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-acti­vated receptor-gamma. J Exp Med 2005; 201(8): 1205–1215.

10. Dubuquoy L, Dharancy S, Nutten S et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360(9343): 1410–1418.

11. Myers B, Evans DN, Rhodes J et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28(2): 196–200.

12. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17(1): 29–42.

13. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298(6666): 82–86.

14. Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008; 2(3): 299–314.

15. Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009; 15(35): 4353–4355.

16. Lukáš M. Účinnost udržovací terapie u ulcerózni kolitidy je ovlivněna farmakokinetikou mesalazinu a adherencí k medikamentózní lecbe. Komentář ke studii PODIUM. Čes a Slov Gastroent a Hepatol 2010; 64(5): 26–29.

17. Dignass AU, Bokemeyer B, Adamek H et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastro­enterol Hepatol 2009; 7(7): 762–769.

18. Kruis W, Kiudelis G, Racz I et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58(2): 233–240.

19. Flourie B. Once-Daily versus Twice-daily Mesalazine (Pentasa) for Active Ulcerative Colitis: Efficacy Results from MOTUS, a Multicentre, Controlled, Randomised, ­Investigator-Blinded Study. Gut 2011.

20. Cerveny P, Bortlik M, Kubena A et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13(10): 1244–1249.

21. Kane SV, Cohen RD, Aikens JE et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96(10): 2929–2933.

22. Kane S, Huo D, Aikens J et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114(1): 39–43.

23. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2(4947): 1041–1048.

24. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9(3): 293–300.

25. Sutherland L, Macdonald JK. Oral ­5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD000543.

26. Hanauer SB, Sandborn WJ, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100(11): 2478–2485.

27. Ford AC, Achkar JP, Khan KJ et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 601–616.

28. Sutherland L, Macdonald JK. Oral ­5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD000544.

29. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn´s disease: Current management. J Crohns Colitis 2010; 4(1): 28–62.

30. Bokemeyer B, Katalinic A, Klugmann T et al. Predictive factors for a mild course of Crohn´s disease. J Crohns Colitis 2009; 3: S82–S83.

31. Duricova D, Pedersen N, Elkjaer M et al. 5-Aminosalicylic acid dependency in Crohn´s disease: A Danish Crohn Colitis Database study. J Crohns Colitis 2010; 4(5): 575–581.

32. Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 617–629.

33. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 2010; CD008870.

34. Travis SP, Stange EF, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55 (Suppl 1): i16–i35.

35. Van AG, Dignass A, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J ­Crohns Colitis 2010; 4(1): 63–101.

36. Ford AC, Khan KJ, Talley NJ et al. ­5-aminosalicylates prevent relapse of ­Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(3): 413–420.

37. Gordon M, Naidoo K, Thomas AG et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2011; CD008414.

38. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571–607.

39. Loftus EV Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19(2): 179–189.

40. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13(5): 629–638.

41. Van Staa TP, Travis S, Leufkens HG et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemio­logic study. Gastroenterology 2004; 126(7): 1733–1739.

42. Jess T, Gamborg M, Matzen P et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100(12): 2724–2729.

43. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10(6): 639–645.

44. Biancone L, Michetti P, Travis S et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2(1): 63–92.

45. Rubin DT, Cruz-Correa MR, Gasche C et al. Colorectal cancer prevention in inflammatory bowel disease and the role of ­5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008; 14(2): 265–274.

46. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48(4): 526–535.

47. van der Woude CJ, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4(5): 493–510.

48. Adamcová M, Bajer M, Bajerová K et al. Doporučení Pracovní skupiny dětské gastro­enterologie a výživy ČPS pro dia­gnostiku a léčbu nespecifických střevních zánětů u dětí. Cesko-Slovenska Pediatrie 2012; 67: 5–47.

Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Article was published in

Gastroenterology and Hepatology

Issue 5

2012 Issue 5

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account